In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.

Ocio, Enrique M; Vilanova, David; Atadja, Peter; Maiso, Patricia; Crusoe, Edvan; Fernández-Lázaro, Diego; Garayoa, Mercedes; San-Segundo, Laura; Hernández-Iglesias, Teresa; de Alava, Enrique; Shao, Wenlin; Yao, Yung-Mae; Pandiella, Atanasio; San-Miguel, Jesús F

Ocio, Enrique M; Vilanova, David; Atadja, Peter; Maiso, Patricia; Crusoe, Edvan; Fernández-Lázaro, Diego; Garayoa, Mercedes; San-Segundo, Laura; Hernández-Iglesias, Teresa; de Alava, Enrique; Shao, Wenlin; Yao, Yung-Mae; Pandiella, Atanasio; San-Miguel, Jesús F.

Affiliation

Ocio EM; Department of Hematology, University Hospital & Cancer Research Center, University of Salamanca P San Vicente, 58-182, 37007 Salamanca, Spain. emocio@usal.es

Haematologica ; 95(5): 794-803, 2010 May.

Article in En | MEDLINE | ID: mdl-19951978

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/administration & dosage; Multiple Myeloma/drug therapy; Multiple Myeloma/pathology; Animals; Boronic Acids/administration & dosage; Bortezomib; Cell Line, Tumor; Cells, Cultured; Dexamethasone/administration & dosage; Disease Models, Animal; Humans; Hydroxamic Acids/administration & dosage; Indoles; Lenalidomide; Mice; Mice, SCID; Panobinostat; Pyrazines/administration & dosage; Random Allocation; Thalidomide/administration & dosage; Thalidomide/analogs & derivatives; Xenograft Model Antitumor Assays

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Multiple Myeloma Type of study: Clinical_trials Limits: Animals / Humans Language: En Journal: Haematologica Year: 2010 Type: Article Affiliation country: Spain

Fulltext

XML

PubMed Links

Search on Google